The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

The biopharma company's stock fell as much as 3.60 per cent during the day to ₹331 per share, the lowest level since June 6 ...

Biocon Ltd (BOM:532523) reports a robust 15% increase in operating revenue, driven by biosimilars and CRDMO growth, despite ...

Trading at Rs 367.85, Biocon shows a positive move in today's early trading session, with the stock included in the Nifty Midcap 150 index.

Biocon Limited ( ($IN:BIOCON) ) has provided an update. Biocon Limited has released the transcript of its Q1 FY26 earnings call, which was held on ...

Revenue from operations, however, grew 1 4.8% YoY to ₹3,942 crore, against ₹3,433 crore in the year-ago period. This figure ...

Motilal Oswal is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 410 in its research ...

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive ...

Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

Biocon Ltd. reported a 95% fall in net profit for the first quarter of financial year 2026. The pharma company reported a ...

Biocon's consolidated net profit plummeted by 95% to Rs 31 crore in the June quarter, with total revenue declining to Rs ...